Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

8279.TWO

STRONG BUYFLAG

Syngen Biotech Co.,Ltd. · Healthcare · Taiwan · $82M · Avg Vol: $53K/d

87
StockRank
Q
68
V
82
M
26
P/E (TTM)
9.9x
ROE
11.0%
D/E
0.1x
Dividend %
5.2%
Director Trades · 180d
None in 180d →
Buybacks · 180d
None in 180d →
AI CONVICTION THESIS

Syngen Biotech operates in the microbial fermentation and active ingredient space, aligning with the CDMO theme. However, it lacks the global scale, regulatory moats, and high-barrier biologics capabilities of leading Western CDMOs, making its pricing power less secure.

COMPANY DESCRIPTION

Syngen Biotech Co., Ltd. specializes in microbial fermentation technology, manufacturing high-quality probiotics, enzymes, and active pharmaceutical ingredients (APIs). The company's competitive advantage is derived from its advanced strain selection, high-density fermentation, and proprietary microencapsulation technologies that ensure probiotic stability. Syngen operates as a leading ODM/OEM partner for global health supplement and pharmaceutical brands.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGR
Revenue—61.0M58.0M63.6M67.5M3.4%
EPS0.280.370.320.28—0.3%
Shares—27.1M27.1M27.1M27.1M0.0%
Debt—24.9M21.5M17.2M10.0M-26.2%
Equity—62.9M67.4M70.7M75.0M6.0%
Op CF—8.8M13.1M11.0M10.1M4.8%
Inv CF—-18.5M-3.0M-2.7M-2.4M—
Fin CF—7.5M-6.3M-9.1M-9.8M—
Loading...
PRICE (1Y)-8.0%
2.882.943.003.073.13May 14Jun 4Jun 25
SMA 50SMA 200
Close
$2.88
RSI (14)
46.8
52W High
$4.22
From 52W High
0.7%

SCORE BREAKDOWN

Quality
68
ROIC
13.5%81.8
ROE
11.0%74.3
GP/Assets
22.7%51.8
Op. Margin
10.4%67.0
FCF/Assets
8.7%83.2
Piotroski
782.3
Int. Cover
50.0x88.4
D/E Ratio
0.07x70.4
Current Ratio
1.84x33.9
Value
82
P/E (TTM)
9.9x88.0
EV/EBITDA
7.7x79.7
P/FCF
309.1x82.1
P/B
1.5x71.4
P/S
1.3x78.8
Div Yield
5.2%91.1
Momentum
26
52W High %
68%54.6
RS 6M
-84%10.0
SMA 50/200
0.85x21.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-45%11.8

FUNDAMENTALS

Market Cap
$82M
P/E (Forward)
—
Gross Margin
33.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 8279.TWO are excluded.

TickerCompanyMkt CapStockRankSignal
8279.TWOSyngen Biotech Co.,Ltd.(you)$82M87STRONG BUY
1733.TWApex Biotechnology Corp.$93M91STRONG BUY
1762.TWChunghwa Chemical Synthesis & Biotech Co., Ltd.$87M76BUY
1734.TWSinphar Pharmaceutical Co.,Ltd.$193M85STRONG BUY
4167.TWOSavior Lifetec Corporation$193M80STRONG BUY
1760.TWPanion & Bf Biotech Inc.$163M77BUY
4162.TWOPharmaEngine, Inc.$256M74BUY
4728.TWOSunmax Biotechnology Co., Ltd.$648M78BUY
6634.TWOSinew Pharma Inc.$143M35SELL
4130.TWOGenovate Biotechnology Co., Ltd.$109M29SELL

Peer medians: ROE 3.4% · P/E 16.4x · Gross margin 42.1%

Syngen Biotech Co.,Ltd. (8279.TWO) — Stock Score Summary

Syngen Biotech Co.,Ltd. (8279.TWO) has a MoatMap StockRank of 87/100 based on Quality (68/100), Value (82/100), and Momentum (26/100) factor scores. The current signal is STRONG BUY. Syngen Biotech operates in the microbial fermentation and active ingredient space, aligning with the CDMO theme. However, it lacks the global scale, regulatory moats, and high-barrier biologics capabilities of leading Western CDMOs, making its pricing power less secure.

Syngen Biotech Co., Ltd. specializes in microbial fermentation technology, manufacturing high-quality probiotics, enzymes, and active pharmaceutical ingredients (APIs). The company's competitive advantage is derived from its advanced strain selection, high-density fermentation, and proprietary microencapsulation technologies that ensure probiotic stability. Syngen operates as a leading ODM/OEM partner for global health supplement and pharmaceutical brands.

Key Financial Metrics

Price$2.88
Market Cap$82M
P/E (TTM)9.89
Price/Book1.45
Return on Equity11.0%
Return on Invested Capital13.5%
Debt/Equity7.29
Gross Margin33.2%
Operating Margin10.4%
Revenue Growth-14.3%
Dividend Yield5.2%
Free Cash Flow$264K

Syngen Biotech Co.,Ltd. operates in the Biotechnology industry, part of the Healthcare sector (Taiwan).

Frequently Asked Questions

What is Syngen Biotech Co.,Ltd.’s (8279.TWO) StockRank?
MoatMap’s StockRank for Syngen Biotech Co.,Ltd. (8279.TWO) is 87/100, with a Strong Buy signal. It is a composite of Quality (68), Value (82), and Momentum (26) factor ranks across MoatMap’s 20,000+ stock universe.
Does Syngen Biotech Co.,Ltd. have an economic moat?
Syngen Biotech Co.,Ltd. (8279.TWO) has a Quality factor score of 68/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Syngen Biotech Co.,Ltd. a buy, hold, or sell?
MoatMap’s current signal for Syngen Biotech Co.,Ltd. (8279.TWO) is Strong Buy, based on a StockRank of 87/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Syngen Biotech Co.,Ltd. in?
Syngen Biotech Co.,Ltd. (8279.TWO) operates in the Healthcare sector, specifically the Biotechnology industry (Taiwan).
Browse all ranked stocks8279.TWO deep dive reportAI ChampionsHow we score stocksSense-check another stock